Lorena Tonarelli M.Sc.

Medical Writer, Copywriter,     and Journalist

Medical Writing




A senior consultant in market access and medical communications, Lorena has over 15 years of professional experience in medical writing and editing. She works with market access consultancies, med comms agencies, clinical research organisations and pharma companies on a wide range of products, therapy areas and drug classes. Lorena is a member of the European Medical Writers Association (EMWA).  She has a degree of Master of Science in Science and a bachelor's degree (Hons) in Natural Sciences.


Global value dossiers • Key value message development and testing • Value stories and propositions • Core value slide decks • payer/KOL discussion guides • Value strategy projects • Advisory board/KOL meeting reports • Abstracts, posters and slide decks for presentation at conferences • Manuscripts for publication in medical journals • Publication plans • Symposium reviews • Clinical summaries • Publication summaries • Reference packs • Objection handlers • Project proposals • Quality control (QC) • Educational content •

Therapy areas

Oncology (haematologic and solid tumours) • Psoriasis • Rare diseases (cystic fibrosis) • ADHD • Immunodeficiency diseases • Asthma • COPD • Haematology (anaemia, haemophilia) • Ophthalmology (AMD, glaucoma, diabetic retinopathy, retinoblastoma) • Cardiovascular (stroke, myocardial infarction, cardiac arrest, heart failure, arrhythmias) • Diabetes and related complications (nephropathy, retinopathy) • Neurology (Alzheimer’s disease and other dementias, Parkinson’s disease, multiple sclerosis, epilepsy) • Rheumatology •

Drug classes

Checkpoint inhibitors (e.g., anti PD-1/PD-L1 and CTLA-4 mAbs) • LADD-based immunotherapies • PARP inhibitors • Tyrosine kinase inhibitors (e.g., VEGFR TKIs, HER2 TKIs) • CDK4/6 inhibitors • EGFR/cMet bispecific antibodies • Anti-CD30 antibody-drug conjugates • PCSK9 inhibitors • SGLT2 inhibitors • Anti-TNF monoclonal antibodies • IL-23 inhibitors • LAMAs, LABAs • Nonstimulant selective alpha2A-adrenergic receptor agonists • Immunoglobulins • CFTR potentiators • (List is not exhaustive)


In-depth understanding of clinical trials and the pharmaceutical product’s life cycle • Interprets and presents, as text and graphically, clinical as well as budget impact (BI) and cost-effectiveness (CE) data • Familiar with PubMed searches,  reference mark-up, and EndNote use • Supports clients throughout projects, by applying expert therapy area and product knowledge, attending meetings, and addressing amendment requests • Reviews the work of others, including medical writers, KOLs and researchers •


Envision Pharma Group • PAREXEL International Corporation • Bedrock Healthcare Communications • RJW & Partners • E-vate • Porterhouse Medical Group • The European Medical Journal (EMJ) • Celgene Corporation • Novartis Oncology • Medtronic • DDB Remedy • Hayward Medical Communications • Johnson & Johnson • Merck Serono • Pfizer UK • Chandler Chicco Agency • Freiberg Press Inc. • Bupa UK • Curated Digital • Insight-2-Implement • General Electric (GE) Healthcare •

Print Print | Sitemap
© 2019 Lorena Tonarelli, M.Sc. B.Sc. (Hons)